Analyst Reco. Johnson & Johnson Buenos Aires S.E.

Equities

JNJD

ARDEUT110236

End-of-day quote Buenos Aires S.E. Other stock markets 06:00:00 2024-07-04 pm EDT			5-day change	1st Jan Change
9.85 ^USD	-0.51%		-1.20%	-3.43%

Jul. 03	Johnson & Johnson's Rybrevant Approved by Health Canada to Treat Advanced Lung Cancer	MT
Jul. 03	Johnson & Johnson Lung Cancer Drug Gets Health Canada Approval	DJ

Analyst Reco.

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Citigroup Adjusts Price Target on Johnson & Johnson to $180 From $185, Keeps Buy Rating	Jun. 06	MT
Guggenheim Adjusts Johnson & Johnson's Price Target to $160 From $167	May. 01	MT
Redburn Atlantic Adjusts Johnson & Johnson Price Target to $160 From $170	Apr. 25	MT
Daiwa Securities Adjusts Johnson & Johnson's Price Target to $160 From $170, Maintains Outperform Rating	Apr. 22	MT
HSBC Upgrades Johnson & Johnson to Buy From Hold, Raises Price Target to $170 From $169	Apr. 18	MT
DZ Bank Adjusts Johnson & Johnson's Price Target to $176 From $181, Maintains Buy Rating	Apr. 18	MT
Bernstein Adjusts Johnson & Johnson's Price Target to $161 From $172, Maintains Market Perform Rating	Apr. 18	MT
BofA Securities Adjusts Price Target on Johnson & Johnson to $170 From $180, Maintains Neutral Rating	Apr. 17	MT
Morgan Stanley Adjusts Johnson & Johnson's Price Target to $167 From $168, Keeps Equalweight Rating	Apr. 17	MT
RBC Adjusts Johnson & Johnson's Price Target to $175 From $181, Keeps Outperform Rating	Apr. 17	MT
Raymond James Adjusts Johnson & Johnson's Price Target to $170 From $175, Maintains Outperform Rating	Apr. 17	MT
Stifel Cuts Johnson & Johnson's Price Target to $155 From $160	Apr. 16	MT
Morgan Stanley Trims Price Target on Johnson & Johnson to $168 From $169, Keeps Equalweight Rating	Apr. 09	MT
Johnson & Johnson Recommends Shareholders to Reject TRC Capital Investment's Mini-Tender Offer	Apr. 05	MT
J&J recommends shareholders to reject 'mini-tender' offer by TRC Capital Investment	Apr. 04	RE
Guggenheim Trims Price Target on Johnson & Johnson to $167 From $169, Maintains Neutral Rating	Jan. 24	MT
Morgan Stanley Adjusts Price Target on Johnson & Johnson to $169 From $170, Maintains Equalweight Rating	Jan. 24	MT
B. Riley Downgrades Ambrx Biopharma to Neutral From Buy on Heels of Announced Sale to Johnson & Johnson, Adjusts PT to $28 From $26	Jan. 09	MT
Raymond James Raises Johnson & Johnson's Price Target to $175 From $172, Maintains Outperform Rating	Jan. 03	MT
ANALYST RECOMMENDATIONS : Adobe, Airbnb, Netflix, Nike, Etsy...	Dec. 14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Joseph Wolk, CFO of J&J: End of patent for its flagship drug

January 23, 2024 at 12:30 pm EST